The Effect of Agomelatine on the Nociceptive System

Kıvrak, Yüksel; Karademir, Başaran; Aygün, Hayati; Ersan, Yusuf; Arı, Mustafa; Karaahmet, Elif; Yağcı, İbrahim

doi:10.5455/bcp.20130925022745

Cited by 3 publications

(2 citation statements)

References 33 publications

(35 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The agomelatine groups had larger pain thresholds than the control group. In comparison to the other research groups, group B’s pain threshold was greater after 30 min [ 24 ].The study of Ozcan et al revealed that agomelatine could augment the anti-nociceptive effects of morphine in the mice model of diabetic neuropathy [ 25 ]. The potential of anti-nociceptive effects of agomelatine, besides its anti-neuropathic effects, further support its implication to treat CLBP.…”

Section: Discussionmentioning

confidence: 96%

The effectiveness of pregabalin with or without agomelatine in the treatment of chronic low back pain: a double-blind, placebo-controlled, randomized clinical trial

Mahdavi

Shariati

Shalbafan

et al. 2022

BMC Pharmacol Toxicol

View full text Add to dashboard Cite

Background Although various pharmacological and nonpharmacological treatments are available for the chronic low back pain (CLBP), there is no consensus on the best optimal treatment for this condition. This study aimed to investigate the efficacy of co-administration of pregabalin and agomelatine versus pregabalin with placebo to treat CLBP. Methods Forty-six CLBP patients without the surgical indication referred to the outpatient orthopedic clinic of Rasoul-e-Akram Hospital, Tehran, Iran, were randomly divided into two study groups: Group A [pregabalin (75 mg twice per day) + placebo] and Group B [pregabalin (75 mg twice per day) + agomelatine (25 mg per night)]. Patients were evaluated at weeks 0, 4, and 8. Outcome measures were the Persian versions of the Brief Pain Inventory (BPI) interference scale, Roland-Morris Disability Questionnaire (RMDQ), The Hospital Anxiety and Depression Scale (HADS), 36-Item Short Form Survey (SF-36), and General Health Questionnaire-28 (GHQ-28) were used. Results At weeks 4 and 8 after the intervention, all evaluated measures showed significant improvement in both study groups (P < 0.01). The mean improvement of GHQ-28 was 3.7 ± 1.22 in group A and 13.1 ± 4.71 in group B. This difference was statistically significant (P = 0.003). Other outcomes did not vary substantially between the two research groups. Agomelatine treatment was well tolerated, with no significant adverse effects seen in patients. Liver tests of all patients were routine during the study period. Major adverse effect was not seen in any patient. The prevalence of Minor side effects was not significantly different between two study groups. Conclusion Compared with the pregabalin and placebo, co-administration of pregabalin and agomelatine had no added effect on improving pain scores in CLBP patients. However, the patients’ general health was significantly improved after the combined administration of pregabalin and agomelatine. Trial registration The study protocol was registered in the Iranian Registry of Clinical Trials before starting the study (NO.IRCT20200620047852N1, Registration date: 23/06/2020).

show abstract

Section: Discussionmentioning

confidence: 96%

The effectiveness of pregabalin with or without agomelatine in the treatment of chronic low back pain: a double-blind, placebo-controlled, randomized clinical trial

Mahdavi

Shariati

Shalbafan

et al. 2022

BMC Pharmacol Toxicol

View full text Add to dashboard Cite

show abstract

“…Psychiatric disorders are among the most prevalent diseases [ 7 , 8 ]. The SSRIs are prescribed by both psychiatrists and nonpsychiatrist clinicians.…”

Section: Discussionmentioning

confidence: 99%

Diffuse Hair Loss Induced by Sertraline Use

Kıvrak

Yağcı

Üstündağ

et al. 2015

Case Reports in Psychiatry

View full text Add to dashboard Cite

Hair loss is a rare side effect of psychotropic drugs. The most related drug class with this side effect is the mood stabilizers. Studies reporting the sertraline-induced alopecia are limited in number. Sertraline is a potent antidepressant which inhibits the serotonin reuptake from the presynaptic terminals selectively. The reason for hair loss could not be elucidated completely. Psychotropic drugs are usually considered to lead to hair loss through influencing the telogen phase of hair follicle. This paper reports a 21-year-old male with diffuse hair loss induced by sertraline use and improved by quitting the drug. To the best of our knowledge, there are no other case reports on sertraline-induced alopecia within 2 weeks.

show abstract

Opioid system mediated anti-nociceptive effect of agomelatine in mice

Kasap

Can

2016

Life Sciences

View full text Add to dashboard Cite

The Effect of Agomelatine on the Nociceptive System

Cited by 3 publications

References 33 publications

The effectiveness of pregabalin with or without agomelatine in the treatment of chronic low back pain: a double-blind, placebo-controlled, randomized clinical trial

The effectiveness of pregabalin with or without agomelatine in the treatment of chronic low back pain: a double-blind, placebo-controlled, randomized clinical trial

Diffuse Hair Loss Induced by Sertraline Use

Opioid system mediated anti-nociceptive effect of agomelatine in mice

Contact Info

Product

Resources

About